Skip to main content
$0.72 +0.05 (+7.46%) At close · Jul 28
Market Cap
$13.10M
Shares
11.70M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.72 Open$0.67 Day$0.67–0.73 52W$0.54–1.87 Avg vol 30d14K Short int32K · 0.3% float · 1.1d Short vol26% Last earningsNov 9, 2023 DataJan 2020–Jul 2026 Filing10-Q · May 14

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 18.2 · elevated Equity put/call 0.71
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −22%
below
Price vs 50-day avg +3%
above
RSI (14) 55
neutral
MACD trend Negative
52-week position 14%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +3%
trailing
6-month return +13%
trailing
YTD return −36%
this year
Relative strength +6%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-92% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.28% of float · ▲ +952.7% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Squeeze score 41
elevated · 0–100
Fundamentals
Fair
Revenue growth −100%
Y/Y
EPS growth +96%
Y/Y
Free cash flow $-4.4M
Balance sheet $14.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 79%
annualized · 1-yr
Max drawdown −69%
past year
ATR 5.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−22% Bearish
Price vs 50-day avg
+3% Bullish
RSI (14)
55 Neutral
MACD trend
Negative Bearish
52-week position
14% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-92% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.28% of float · ▲ +952.7% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $1 Now $1 · 14% 52-wk high $2
vs 200-day avg -22% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SYBX
Synlogic, Inc.
this stock
$13.10M -35.7% -99.8% 0.3%
ONC
BeOne Medicines Ltd.
$472.90B +8.8% +22179.2% 962.4 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$124.46B +8.2% +46.2% 29.1 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
$72.88B -9.8% +20.8% 17.0 3.3%
ARGX
Argenx SE
$54.57B +3.7% 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
2
% held
0.2%
Net QoQ
-6.9M sh
Top holder
DRW Securities, LLC
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
32.4K
Days to cover
1.1d
Change
+29.3K sh
View
Short Volume
Short vol %
26%
As of
Jul 29, 2026
Short Total
View
Fails to Deliver
FTD shares
50
Value
$34
As of
May 29, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
May 4, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-1.0M
EPS diluted
$-0.08
View
Buybacks
Authorized
shares 1.2M
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 29, 2026
This year
6
View
Proposed Sales
Value
$161.6K
Shares
88.3K
Filed
Apr 22, 2024
View
Earnings & Events
Earnings Calls
Last call
Nov 9, 2023
View

Performance

5D 20D 120D MTD YTD
SYBX +2.1% +2.7% +13.4% +2.7% -35.7%
SPY -1.0% 0.0% +7.4% -0.8% +8.6%
vs SPY +3.1% +2.7% +6.0% +3.5% -44.4%

Capital returns

Buyback program · as of Sep 30, 2017
Authorized
shares 1.22M
Spent (derived)
Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1527599 CUSIP 87166L209 Visit website